Vivek Subbiah/LinkedIn
May 12, 2025, 08:57
Vivek Subbiah: Enlightening discussions with Dr. Johanna Bendell
Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute, shared on LinkedIn:
“It was an absolute pleasure to host and engage in wide ranging enlightening discussions with the terrific and one and only Dr. Johanna Bendell.
Her depth of insight and breadth of knowledge are truly remarkable – wow. like wisdom of reading 10 books and the intensity of 10 action-packed films in just a few hours.
My sincerest congratulations to her as she embarks on this new journey as Chief Development Officer, Oncology Pfizer
Wishing her continued success in this distinguished role and looking forward to partner to help patients with cancer access cutting edge therapies. Thank you for visiting Nashville Sarah Cannon Research Institute.”
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 17:27
Jul 19, 2025, 17:26
Jul 19, 2025, 16:48
Jul 19, 2025, 16:41
Jul 19, 2025, 16:06
Jul 19, 2025, 16:04
Jul 19, 2025, 15:58